PDCD1 and metastatic melanoma: Nevertheless, the study by Tumeh et al. shows that an increase in CD8+ T cell density both at the invasive margin or tumor parenchyma predicts favorable clinical responses for metastatic melanoma receiving anti-PD-1 inhibitors, providing inconsistent evidence against the general “hot” and “cold” tumor theory [106].